Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy

Hoffman, 1987, Dystrophin – the protein product of the duchenne muscular-dystrophy locus, Cell, 51, 919, 10.1016/0092-8674(87)90579-4 Deconinck, 2007, Pathophysiology of duchenne muscular dystrophy: current hypotheses, Pediatr Neurol, 36, 1, 10.1016/j.pediatrneurol.2006.09.016 Campbell, 1995, Three muscular dystrophies; loss of cytoskeleton-extracellular matrix linkage, Cell, 80, 675, 10.1016/0092-8674(95)90344-5 Tidball, 2005, Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis, Curr Opin Rheumatol, 17, 707, 10.1097/01.bor.0000179948.65895.1a Tidball, 2004, Evolving therapeutic strategies for duchenne muscular dystrophy: targeting downstream events, Pediatr Res, 56, 831, 10.1203/01.PDR.0000145578.01985.D0 Bushby, 2010, Diagnosis and management of duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management, Lancet Neurol, 9, 77, 10.1016/S1474-4422(09)70271-6 Collins, 2003, Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies, Int J Exp Pathol, 84, 165, 10.1046/j.1365-2613.2003.00354.x Partridge, 1991, Animal-models of muscular dystrophy – what can they teach us, Neuropathol Appl Neurobiol, 17, 353, 10.1111/j.1365-2990.1991.tb00735.x Villalta, 2009, Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy, Hum Mol Genet, 18, 482, 10.1093/hmg/ddn376 Bhatnagar, 2010, Therapeutic targeting of signaling pathways in muscular dystrophy, J Mol Med (Berl), 88, 155, 10.1007/s00109-009-0550-4 Handschin, 2007, PGC-1 alpha regulates the neuromuscular junction program and ameliorates duchenne muscular dystrophy, Genes Dev, 21, 770, 10.1101/gad.1525107 Lin, 2002, Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres, Nature, 418, 797, 10.1038/nature00904 Michel, 2007, Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression, Appl Physiol Nutr Metab, 32, 921, 10.1139/H07-093 Selsby, 2012, Rescue of dystrophic skeletal muscle by PGC-1 alpha involves a fast to slow fiber type shift in the mdx mouse, Plos One, 10.1371/journal.pone.0030063 Chakkalakal, 2006, Targeted inhibition of Ca2+/calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle, Hum Mol Genet, 15, 1423, 10.1093/hmg/ddl065 Guevel, 2011, Quantitative proteomic analysis of dystrophic dog muscle, J Proteome Res, 10, 2465, 10.1021/pr2001385 Squire, 2002, Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system, Hum Mol Genet, 11, 3333, 10.1093/hmg/11.26.3333 Lagouge, 2006, Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha, Cell, 127, 1109, 10.1016/j.cell.2006.11.013 Elmali, 2007, Effects of resveratrol on skeletal muscle in ischemia-reperfusion injury, Ulus Travma Acil Cerrahi Derg, 13, 274 Murase, 2009, Suppression of the aging-associated decline in physical performance by a combination of resveratrol intake and habitual exercise in senescence-accelerated mice, Biogerontology, 10, 423, 10.1007/s10522-008-9177-z Jackson, 2011, Long-term supplementation with resveratrol alleviates oxidative stress but does not attenuate sarcopenia in aged mice, J Gerontol A Biol Sci Med Sci, 751, 10.1093/gerona/glr047 Moorwood, 2011, Drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening, PLoS One, 6, 10.1371/journal.pone.0026169 Hori, 2011, Resveratrol ameliorates muscular pathology in the dystrophin mdx mouse, a model for duchenne muscular dystrophy, J Pharmacol Exp Ther, 338, 784, 10.1124/jpet.111.183210 Zhang, 2010, Roles of SIRT1 in the acute and restorative phases following induction of inflammation, J Biol Chem, 285, 41391, 10.1074/jbc.M110.174482 Regnault, 2010 Laing, 2009, Resveratrol alleviates alcoholic fatty liver in mice, Alcoholism-clinical Exp Res, 33, 161A Planavila, 2010, Sirt1 acts in association with PPAR alpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation, Cardiovasc Res, 90, 276, 10.1093/cvr/cvq376 Delgado-Diaz, 2011, Therapeutic ultrasound affects IGF-1 splice variant expression in human skeletal muscle, Am J Sports Med, 39, 2233, 10.1177/0363546511414857 Bradford, 1976, A rapid and sensititive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding, Anal Biochem, 72, 248, 10.1016/0003-2697(76)90527-3 Spencer, 2001, Helper (CD4(+)) and cytotoxic (CD8(+))T cells promote the pathology of dystrophin-deficient muscle, Clin Immunol, 98, 235, 10.1006/clim.2000.4966 Evans, 2009, Immune mediated mechanisms potentially regulate the disease time course of duchenne muscular dystrophy and provide targets for therapeutic intervention, PMR, 1, 755, 10.1016/j.pmrj.2009.04.010 Wehling, 2001, A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice, J Cell Biol, 155, 123, 10.1083/jcb.200105110 Rafael, 1998, Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice, Nat Genet, 19, 79, 10.1038/ng0598-79 Wright, 2007, Exercise-induced mitochondrial biogenesis begins before the increase in muscle PGC-1 alpha expression, J Biol Chem, 282, 194, 10.1074/jbc.M606116200 Miura, 2005, The utrophin a 5' untranslated region confers internal ribosome entry site mediated translational control during regeneration of skeletal muscle fibers, J Biol Chem, 280, 32997, 10.1074/jbc.M503994200 Khurana, 1991, Immunolocalization and developmental expression of dystrohin related protein in skeletal muscle, Neurmuscul Disord, 1, 185, 10.1016/0960-8966(91)90023-L Chang, 2006, Myogenic basic helix-loop-helix proteins regulate the expression of peroxisomal proliferator activated receptor-gamma coactivator-1 alpha, Endocrinology, 147, 3093, 10.1210/en.2005-1317 Fujimori, 2002, Interleukin 6 induces overexpression of the sarcolemmal utrophin in neonatal mdx skeletal muscle, Hum Gene Ther, 13, 509, 10.1089/10430340252809801 Pedersen, 2007, IL-6 signalling in exercise and disease, Biochem Soc Trans, 35, 1295, 10.1042/BST0351295